KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
Form S-8 KalVista Pharmaceuticals
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Arif Bilal
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Sweeny Nicole
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Audhya Paul K.
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Piekos Brian
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.